Direct oral anticoagulant (DOAC) therapy in patients with non-valvular atrial fibrillation (AF) was associated with a significantly lower risk of death compared with no anticoagulation, in a retrospective cohort study, published in Heart. In this cohort of newly diagnosed patients with moderate- to high-risk non-valvular AF treated in routine clinical practice, DOAC therapy was associated with a 31% reduction in all-cause mortality.